A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Therapeutic Use
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 29 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
- 12 Nov 2018 New trial record